Trials / Completed
CompletedNCT03156023
Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis
A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate safety and tolerability and characterize the pharmacokinetic (PK) profile of rozibafusp alfa following multiple dose administration in adults with rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rozibafusp Alfa | Administered by subcutaneous injection once every 2 weeks. |
| DRUG | Placebo | Administered by subcutaneous injection once every 2 weeks. |
Timeline
- Start date
- 2017-08-14
- Primary completion
- 2019-10-17
- Completion
- 2020-06-12
- First posted
- 2017-05-16
- Last updated
- 2024-05-14
- Results posted
- 2023-04-03
Locations
4 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03156023. Inclusion in this directory is not an endorsement.